AU2015315005B9 - Immunogenic mutant peptide screening platform - Google Patents

Immunogenic mutant peptide screening platform Download PDF

Info

Publication number
AU2015315005B9
AU2015315005B9 AU2015315005A AU2015315005A AU2015315005B9 AU 2015315005 B9 AU2015315005 B9 AU 2015315005B9 AU 2015315005 A AU2015315005 A AU 2015315005A AU 2015315005 A AU2015315005 A AU 2015315005A AU 2015315005 B9 AU2015315005 B9 AU 2015315005B9
Authority
AU
Australia
Prior art keywords
peptide
variant
disease
peptides
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015315005A
Other languages
English (en)
Other versions
AU2015315005B2 (en
AU2015315005A1 (en
Inventor
Lelia DELAMARRE
Suchit JHUNJHUNWALA
Jennie Lill
Patrick Lupardus
Ira Mellman
Mahesh YADAV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54238541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015315005(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2015315005A1 publication Critical patent/AU2015315005A1/en
Publication of AU2015315005B2 publication Critical patent/AU2015315005B2/en
Application granted granted Critical
Publication of AU2015315005B9 publication Critical patent/AU2015315005B9/en
Priority to AU2021250887A priority Critical patent/AU2021250887B2/en
Priority to AU2025202619A priority patent/AU2025202619A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
AU2015315005A 2014-09-10 2015-09-10 Immunogenic mutant peptide screening platform Active AU2015315005B9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021250887A AU2021250887B2 (en) 2014-09-10 2021-10-13 Immunogenic mutant peptide screening platform
AU2025202619A AU2025202619A1 (en) 2014-09-10 2025-04-14 Immunogenic mutant peptide screening platform

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048742P 2014-09-10 2014-09-10
US62/048,742 2014-09-10
PCT/US2015/049491 WO2016040682A1 (en) 2014-09-10 2015-09-10 Immunogenic mutant peptide screening platform

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021250887A Division AU2021250887B2 (en) 2014-09-10 2021-10-13 Immunogenic mutant peptide screening platform

Publications (3)

Publication Number Publication Date
AU2015315005A1 AU2015315005A1 (en) 2017-04-06
AU2015315005B2 AU2015315005B2 (en) 2021-07-15
AU2015315005B9 true AU2015315005B9 (en) 2021-08-12

Family

ID=54238541

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015315005A Active AU2015315005B9 (en) 2014-09-10 2015-09-10 Immunogenic mutant peptide screening platform
AU2021250887A Active AU2021250887B2 (en) 2014-09-10 2021-10-13 Immunogenic mutant peptide screening platform
AU2025202619A Pending AU2025202619A1 (en) 2014-09-10 2025-04-14 Immunogenic mutant peptide screening platform

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021250887A Active AU2021250887B2 (en) 2014-09-10 2021-10-13 Immunogenic mutant peptide screening platform
AU2025202619A Pending AU2025202619A1 (en) 2014-09-10 2025-04-14 Immunogenic mutant peptide screening platform

Country Status (7)

Country Link
US (3) US10564165B2 (https=)
EP (2) EP3194970B1 (https=)
JP (4) JP7044551B2 (https=)
CN (2) CN113791220A (https=)
AU (3) AU2015315005B9 (https=)
CA (1) CA2960834A1 (https=)
WO (1) WO2016040682A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP3194970B1 (en) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CA3056212A1 (en) 2016-04-07 2017-10-12 Bostongene Corporation Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
US11927591B2 (en) 2016-08-02 2024-03-12 Georgetown University Methods of identifying novel proteins and antigens in cancer cells
US10350280B2 (en) 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス （アイピー） カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
EP3645028B1 (en) * 2017-06-27 2025-07-09 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center Mhc-1 genotype restricts the oncogenic mutational landscape
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CN119851752A (zh) * 2018-02-27 2025-04-18 磨石生物公司 利用泛等位基因模型进行的新抗原鉴别
US20210020270A1 (en) * 2018-03-08 2021-01-21 The Trustees Of Indiana University Constrained de novo sequencing of neo-epitope peptides using tandem mass spectrometry
WO2019183882A1 (zh) * 2018-03-29 2019-10-03 深圳达闼科技控股有限公司 物质检测方法、装置、电子设备及计算机可读存储介质
EP3807320A4 (en) * 2018-06-12 2022-03-23 BioNTech US Inc. POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS
CA3106562A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
WO2020022899A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
EP3837271A4 (en) * 2018-08-14 2022-06-15 Board of Regents, The University of Texas System SINGLE MOLECULE SEQUENCING PEPTIDES BOUND TO THE MAIN HISTOCOMPATIBILITY COMPLEX
WO2020101037A1 (ja) * 2018-11-16 2020-05-22 株式会社Ｔｎｐパートナーズ オーダーメイド医療基幹システム
CA3115017C (en) 2018-11-21 2023-10-31 Nec Corporation Method and system of targeting epitopes for neoantigen-based immunotherapy
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN112769742B (zh) * 2019-11-06 2024-06-14 电科云(北京)科技有限公司 Spdz系列协议中的消息验证方法、装置及存储介质
CN111863130A (zh) * 2020-04-07 2020-10-30 至本医疗科技（上海）有限公司 肿瘤免疫治疗预后标志物的筛选方法及应用
WO2025101535A1 (en) * 2023-11-07 2025-05-15 Seer, Inc. Biomolecule cleanup methods, kits, and systems

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US47404A (en) 1865-04-25 Improvement in sawing-machines
US1100474A (en) 1914-04-01 1914-06-16 Alfred J Croft Hand-tool.
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
BR9707125A (pt) * 1996-01-11 1999-07-20 Corixa Corp Composições e processos para o tratamento e diagnóstico de câncer de mama
WO1999024566A1 (en) 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO2000020029A1 (en) 1998-10-05 2000-04-13 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
AU1657501A (en) * 1999-11-12 2001-06-06 Regents Of The University Of California, The Determining the functions and interactions of proteins by comparative analysis
WO2001047959A2 (en) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
EP1512014B1 (en) 2002-06-13 2009-08-05 MERCK PATENT GmbH Methods for the identification of all-antigens and their use for cancer therapy and transplantation
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
CA2651796A1 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CA2744449C (en) 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
CA2879024A1 (en) 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
EP3194970B1 (en) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAMMENSEE, HG. et al., "Towards patient-specific tumor antigen selection for vaccination", 2002, Immunological reviews, vol. 188, pages 164-176 *

Also Published As

Publication number Publication date
EP3998481A1 (en) 2022-05-18
JP2021040632A (ja) 2021-03-18
AU2015315005B2 (en) 2021-07-15
JP2017534257A (ja) 2017-11-24
JP7044551B2 (ja) 2022-03-30
JP7592060B2 (ja) 2024-11-29
JP2023027055A (ja) 2023-03-01
AU2021250887A1 (en) 2021-11-11
CN107076762B (zh) 2021-09-10
AU2025202619A1 (en) 2025-05-01
CA2960834A1 (en) 2016-03-17
JP7175951B2 (ja) 2022-11-21
EP3194970B1 (en) 2021-07-28
WO2016040682A1 (en) 2016-03-17
US10564165B2 (en) 2020-02-18
CN113791220A (zh) 2021-12-14
EP3194970A1 (en) 2017-07-26
US20240418731A1 (en) 2024-12-19
AU2015315005A1 (en) 2017-04-06
US12372533B2 (en) 2025-07-29
US20160069895A1 (en) 2016-03-10
US20200124616A1 (en) 2020-04-23
AU2021250887B2 (en) 2025-01-16
CN107076762A (zh) 2017-08-18
JP2024156702A (ja) 2024-11-06

Similar Documents

Publication Publication Date Title
AU2021250887B2 (en) Immunogenic mutant peptide screening platform
TWI668230B (zh) 急性骨髓性白血病（ａｍｌ）等幾種血液腫瘤的新型免疫療法
US10450346B2 (en) Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
EP3157549B1 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
JP2018511321A (ja) 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ
US20210172961A1 (en) Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer
JP2022502015A (ja) がんに対する免疫療法で使用するためのｂ＊４４拘束性ペプチドおよび関連方法
JP2022502358A (ja) がんに対するａ＊０１拘束性ペプチドおよびペプチド組み合わせによる免疫療法
HK40074082A (en) Immunogenic mutant peptide screening platform
CN118475596A (zh) 用于针对纤维板层型肝细胞癌(fl-hcc)和其他癌症的免疫治疗的肽和抗原结合蛋白
HK1242779A1 (en) Immunogenic mutant peptide screening platform
HK1242779B (zh) 免疫原性突变体肽筛选平台
HK40023054A (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
WO2021046616A1 (en) Methods of identifying mhc-bound peptides
HK40005505A (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
HK1236424A1 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
HK1236424B (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
HK1165475A (en) In tumours differentially expressed gene products and use of the same
HK1165462A (en) In tumours differentially expressed gene products and use of the same
HK1165463A (en) In tumours differentially expressed gene products and use of the same

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)